Current Development of Anti-Cancer Drug S-1
نویسندگان
چکیده
منابع مشابه
Anti-cancer drug discovery and development
Deregulated apoptosis is a hallmark of cancer, and the B-cell lymphoma-2 (Bcl-2) family of proteins is pivotal to mediating the intrinsic pathway of this process. Recent advances have yielded both pan-Bcl-2 small molecule inhibitors (SMIs) that inhibit both the Bcl-2 and the Mcl-1 arm of the Bcl-2 family anti-apoptotic proteins, as well as selective SMIs to differentially target the two arms. O...
متن کاملToward the Development of a Single-Round Infection Assay Based on EGFP Reporting for Anti-HIV-1 Drug Discovery
Background: The rapid increase of HIV-1 strains resistant to current antiretroviral drugs is a challenge for successful AIDS therapy. This necessitates the development of novel drugs, and to this end, availability of screening systems for in vitro drug discovery is a priority. Herein, we report the modification of a previously developed system for increased sensitivity, ease of use, and cost-ef...
متن کاملD matrices for anti - cancer Drug testing and Development
U ntil recently, basic research testing the efficacy of novel anti-cancer drugs was performed on cells grown on two-dimensional (2D) glass or plastic platforms. An emerging view finds that traditional 2D cell culture may not accurately mimic the three-dimensional (3D) environment in which cancer cells reside. Specifically, the unnatural 2D environment may provide inaccurate data regarding the p...
متن کاملGenetically Engineered Mouse Models in Preclinical Anti-Cancer Drug Development
According to the most recent American Cancer Society data, an estimated 569,490 Americans died from cancer in 2010 (American Cancer Society [ACS], 2010). The number of cancer-related deaths recently surpassed those from heart disease in Americans <85 yrs old (Kung et al., 2008). Developing new and more efficacious anti-cancer compounds is a paramount health care priority. At the Developmental T...
متن کاملp53 as a target for anti-cancer drug development.
Loss of p53 function compromises genetic homeostasis in cells exhibiting deregulated DNA replication and/or DNA damage, and prevents normal cytotoxic responses to cancer therapies. Genetic and pharmacological approaches are being developed with the ultimate goal of restoring or controlling p53 functions in cancer patients. Progress has recently been made in the clinical use of replication-defic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
سال: 2016
ISSN: 2249-782X
DOI: 10.7860/jcdr/2016/19345.8776